Telisotuzumab vedotin (ABBV-399)
| Telisotuzumab vedotin (ABBV-399) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat solid cancer tumors. |
Type of Molecule
BiologicTarget
cMetProduct Type
New Indication| Potential Indication | Region | Phase (1, 2, 3, Submitted, Approved) |
|---|---|---|
| Solid Tumors | n/a |
Phase 1
|